Vertaling van "tafamidis " (Nederlands → Frans) :

TERMINOLOGIE

product dat tafamidis bevat
produit contenant du tafamidis

product dat enkel tafamidis in orale vorm bevat
produit contenant seulement du tafamidis sous forme orale

product dat tafamidis in orale vorm bevat
produit contenant du tafamidis sous forme orale

IN-CONTEXT TRANSLATIONS

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Speciale populaties Farmacokinetische gegevens wezen op een lagere systemische blootstelling (ongeveer 40%) en hogere totale klaring (0,52 l/u vs. 0,31 l/u) van tafamidis bij patiënten met matige leverinsufficiëntie (Child-Pugh score 7 t/m 9) in vergelijking tot gezonde proefpersonen als gevolg van de grotere ongebonden fractie van tafamidis.
Populations particulières Du fait d’une fraction non liée de tafamidis plus importante, les données de pharmacocinétique montrent une diminution de l’exposition systémique (environ 40%) et une augmentation de la clairance totale (0,52 l/h versus 0,31 l/h) du tafamidis chez les patients présentant une atteinte hépatique modérée (score de Child-Pugh 7 à 9 inclus) comparativement aux sujets sains.

De werkzame stof in dit middel is tafamidis. Elke capsule bevat 20 mg tafamidis (als meglumine).
Chaque capsule contient 20 mg de tafamidis (sous forme de méglumine).

Vyndaqel is een geneesmiddel dat de werkzame stof tafamidis bevat.
Vyndaqel est un médicament qui contient le principe actif tafamidis.

Pediatrische patiënten Er is geen relevante toepassing van tafamidis bij pediatrische patiënten.
Population pédiatrique L’utilisation de Tafamidis n’est pas pertinente dans la population pédiatrique

Elke zachte capsule bevat 20 mg tafamidis (als meglumine).
Chaque capsule molle contient 20 mg de tafamidis (sous forme de méglumine)

Vyndaqel mag niet worden gebruikt bij mensen die overgevoelig (allergisch) zijn voor tafamidis of voor
Vyndaqel ne doit pas être utilisé chez les personnes présentant une hypersensibilité (allergie) au

De werkzame stof in Vyndaqel, tafamidis, stabiliseert transthyretine.
Le principe actif contenu dans Vyndaqel, le tafamidis, est un stabilisateur de la transthyrétine.